Gilead Sciences annual total liabilities
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Total Liabilities Growth & History (GILD)
Gilead Sciences's total liabilities was $36.41B for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $36.41B | −$3.34B | −8.41% |
| 2024 | 2024-12-31 | $39.75B | $373.0M | +0.95% |
| 2023 | 2023-12-31 | $39.38B | −$2.59B | −6.16% |
| 2022 | 2022-12-31 | $41.96B | −$4.93B | −10.51% |
| 2021 | 2021-12-31 | $46.89B | −$3.30B | −6.57% |
| 2020 | 2020-12-31 | $50.19B | $11.21B | +28.76% |
| 2019 | 2019-12-31 | $38.98B | −$3.16B | −7.51% |
| 2018 | 2018-12-31 | $42.14B | −$7.64B | −15.35% |
| 2017 | 2017-12-31 | $49.78B | $12.17B | +32.35% |
| 2016 | 2016-12-31 | $37.61B | $5.01B | +15.37% |
| 2015 | 2015-12-31 | $32.60B | $13.76B | +73.01% |
| 2014 | 2014-12-31 | $18.84B | $8.01B | +73.94% |
| 2013 | 2013-12-31 | $10.83B | −$861.8M | −7.37% |
| 2012 | 2012-12-31 | $11.70B | $1.26B | +12.07% |
| 2011 | 2011-12-31 | $10.44B | $4.97B | +90.76% |
| 2010 | 2010-12-31 | $5.47B | $2.28B | +71.32% |
| 2009 | 2009-12-31 | $3.19B | $722.2M | +29.22% |
| 2008 | 2008-12-31 | $2.47B | — | — |
Gilead Sciences quarterly total liabilities
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $37.62B | $1.49B | +4.12% |
| Q1 2026 | 2026-03-31 | $32.85B | −$4.51B | −12.07% |
| Q4 2025 | 2025-12-31 | $36.41B | −$3.34B | −8.41% |
| Q3 2025 | 2025-09-30 | $37.08B | $942.0M | +2.61% |
| Q2 2025 | 2025-06-30 | $36.13B | $749.0M | +2.12% |
| Q1 2025 | 2025-03-31 | $37.36B | −$1.48B | −3.81% |
| Q4 2024 | 2024-12-31 | $39.75B | $373.0M | +0.95% |
| Q3 2024 | 2024-09-30 | $36.13B | −$4.00B | −9.96% |
| Q2 2024 | 2024-06-30 | $35.38B | −$5.86B | −14.21% |
| Q1 2024 | 2024-03-31 | $38.84B | −$2.10B | −5.13% |
| Q4 2023 | 2023-12-31 | $39.38B | −$2.59B | −6.16% |
| Q3 2023 | 2023-09-30 | $40.13B | −$1.37B | −3.30% |
| Q2 2023 | 2023-06-30 | $41.24B | −$1.41B | −3.31% |
| Q1 2023 | 2023-03-31 | $40.94B | −$2.23B | −5.16% |
| Q4 2022 | 2022-12-31 | $41.96B | −$4.93B | −10.51% |
| Q3 2022 | 2022-09-30 | $41.50B | −$4.13B | −9.05% |
| Q2 2022 | 2022-06-30 | $42.66B | −$5.62B | −11.64% |
| Q1 2022 | 2022-03-31 | $43.16B | −$5.36B | −11.05% |
| Q4 2021 | 2021-12-31 | $46.89B | −$3.30B | −6.57% |
| Q3 2021 | 2021-09-30 | $45.63B | $2.22B | +5.11% |
| Q2 2021 | 2021-06-30 | $48.27B | $10.48B | +27.74% |
| Q1 2021 | 2021-03-31 | $48.53B | $10.97B | +29.19% |
| Q4 2020 | 2020-12-31 | $50.19B | $11.21B | +28.76% |
| Q3 2020 | 2020-09-30 | $43.41B | $5.00B | +13.01% |
| Q2 2020 | 2020-06-30 | $37.79B | −$2.67B | −6.59% |
| Q1 2020 | 2020-03-31 | $37.56B | −$3.18B | −7.81% |
| Q4 2019 | 2019-12-31 | $38.98B | −$3.16B | −7.51% |
| Q3 2019 | 2019-09-30 | $38.41B | −$2.89B | −6.99% |
| Q2 2019 | 2019-06-30 | $40.46B | −$3.16B | −7.25% |
| Q1 2019 | 2019-03-31 | $40.75B | −$3.98B | −8.91% |
| Q4 2018 | 2018-12-31 | $42.14B | −$7.64B | −15.35% |
| Q3 2018 | 2018-09-30 | $41.30B | $1.89B | +4.80% |
| Q2 2018 | 2018-06-30 | $43.62B | $6.45B | +17.35% |
| Q1 2018 | 2018-03-31 | $44.73B | $7.95B | +21.60% |
| Q4 2017 | 2017-12-31 | $49.78B | $12.17B | +32.35% |
| Q3 2017 | 2017-09-30 | $39.41B | $159.0M | +0.41% |
| Q2 2017 | 2017-06-30 | $37.17B | $3.31B | +9.77% |
| Q1 2017 | 2017-03-31 | $36.78B | $3.04B | +9.00% |
| Q4 2016 | 2016-12-31 | $37.61B | $5.01B | +15.37% |
| Q3 2016 | 2016-09-30 | $39.25B | $6.56B | +20.05% |
| Q2 2016 | 2016-06-30 | $33.87B | $11.33B | +50.29% |
| Q1 2016 | 2016-03-31 | $33.75B | $13.01B | +62.76% |
| Q4 2015 | 2015-12-31 | $32.60B | $13.76B | +73.01% |
| Q3 2015 | 2015-09-30 | $32.69B | $17.71B | +118.23% |
| Q2 2015 | 2015-06-30 | $22.53B | $7.76B | +52.49% |
| Q1 2015 | 2015-03-31 | $20.73B | $6.36B | +44.22% |
| Q4 2014 | 2014-12-31 | $18.84B | $8.01B | +73.94% |
| Q3 2014 | 2014-09-30 | $14.98B | $3.70B | +32.86% |
| Q2 2014 | 2014-06-30 | $14.78B | $3.50B | +30.99% |
| Q1 2014 | 2014-03-31 | $14.38B | $2.56B | +21.63% |
| Q4 2013 | 2013-12-31 | $10.83B | −$861.8M | −7.37% |
| Q3 2013 | 2013-09-30 | $11.28B | −$937.7M | −7.68% |
| Q2 2013 | 2013-06-30 | $11.28B | −$1.14B | −9.16% |
| Q1 2013 | 2013-03-31 | $11.82B | −$767.1M | −6.09% |
| Q4 2012 | 2012-12-31 | $11.70B | $1.26B | +12.07% |
| Q3 2012 | 2012-09-30 | $12.21B | $5.81B | +90.64% |
| Q2 2012 | 2012-06-30 | $12.42B | $5.94B | +91.56% |
| Q1 2012 | 2012-03-31 | $12.59B | $5.77B | +84.77% |
| Q4 2011 | 2011-12-31 | $10.44B | $4.97B | +90.76% |
| Q3 2011 | 2011-09-30 | $6.41B | $829.9M | +14.88% |
| Q2 2011 | 2011-06-30 | $6.48B | — | — |
| Q1 2011 | 2011-03-31 | $6.81B | $3.62B | +113.32% |
| Q4 2010 | 2010-12-31 | $5.47B | $2.28B | +71.32% |
| Q3 2010 | 2010-09-30 | $5.58B | $2.39B | +75.11% |
| Q1 2010 | 2010-03-31 | $3.19B | — | — |
| Q4 2009 | 2009-12-31 | $3.19B | $722.2M | +29.22% |
| Q3 2009 | 2009-09-30 | $3.18B | — | — |
| Q2 2009 | 2009-06-30 | $3.07B | — | — |
| Q4 2008 | 2008-12-31 | $2.47B | — | — |
Gilead Sciences total liabilities trends
Over the last five fiscal years, Gilead Sciences's total liabilities decreased from $50.19B to $36.41B, a change of −$13.78B. The latest reported quarter, Q2 2026, shows $37.62B.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
